ABT
Abbott Laboratories
Healthcare · Medical Devices · United States · Stock
Score Breakdown
Scored for Dividend Income profile
Sub-scores are 0–20 each; Model Score is weighted by your selected investment goal. How it works →
Why Ranked Here
- The composite score of 57.0/100 is anchored by strong sub-scores in financial health (18.0/20) and profitability (14.4/20), which collectively contribute over half of the total points earned.
- The dividend sub-score of 13.8/20 adds meaningful weight given Abbott's documented FCF coverage of dividends and DPS growth streak visible in its EDGAR filings, supporting the dividend income goal profile alignment.
- The model's balanced weighting across six dimensions means that Abbott's high scores in defensive metrics partially offset the drag from growth (6.0) and theme (0.0), landing the composite at a mid-range 57.0.
Why Not Higher
- The growth sub-score of 6.0/20 is the single largest drag on the composite score, as limited YoY revenue, net income, and EPS growth as reported in the FY2025 10-K prevent Abbott from scoring in the upper tier.
- A theme score of 0.0/20 means Abbott receives no uplift from macro theme alignment in the model, a structural ceiling that would require demonstrated exposure to at least one qualifying thematic driver to meaningfully improve.
Data Confidence
10 / 10
Very High — full data coverage
Research Summary
AI-generated analysis reflects data and conditions as of the report date shown above. Verify any specific figures through primary sources before acting on this analysis.
Abbott Laboratories is a diversified U.S. healthcare company operating across medical devices, diagnostics, nutrition, and established pharmaceuticals, with major product lines including continuous glucose monitors (FreeStyle Libre), cardiovascular devices, rapid diagnostics, and Ensure nutritional products. The model assigned Abbott a composite score of 57.0/100, reflecting a company that demonstrates meaningful strengths in financial health (18.0/20) and dividend profile (13.8/20), but is held back by modest growth metrics (6.0/20) and near-zero theme exposure (0.0/20). The financial health sub-score indicates a well-capitalized balance sheet with manageable leverage and solid interest coverage as reported in the FY2025 10-K filing, while the dividend sub-score reflects a consistent dividend per share streak, FCF coverage, and sustained DPS growth — characteristics well-suited to the dividend income goal profile where Abbott scores 66.6. The key research tradeoff is between Abbott's stability, income characteristics, and financial discipline on one hand, and its relatively muted revenue and earnings growth trajectory alongside limited alignment with high-growth macro themes on the other.
Plain English
Abbott Laboratories makes medical devices like glucose monitors, diagnostic tests, nutritional drinks like Ensure, and heart-related devices — it is a large, established healthcare company. A model score of 57.0/100 with a Low risk rating suggests Abbott is a financially steady, dividend-oriented research candidate rather than a high-growth opportunity. Its strongest qualities in the data are its balance sheet strength and consistent dividend history, while its growth numbers are relatively modest. Researchers focused on income and stability may find it more relevant than those seeking aggressive earnings expansion.
Bull Case vs. Bear Case
Bull Case
- Abbott's financial health sub-score of 18.0/20 — the highest in its score breakdown — reflects a robust balance sheet with controlled leverage and strong interest coverage as derived from the FY2025 10-K, suggesting a company capable of weathering economic stress.
- The dividend sub-score of 13.8/20 indicates a well-supported dividend profile including consistent DPS growth CAGR, a healthy FCF payout ratio, and a multi-year dividend per share streak, making Abbott a compelling research candidate under the dividend income goal profile where it scores 66.6.
- Abbott's profitability sub-score of 14.4/20 points to solid net and operating margins alongside reasonable return on assets, consistent with a company that has pricing power across its diversified medical device and diagnostics segments.
Bear Case
- The growth sub-score of 6.0/20 is the weakest fundamental pillar in Abbott's profile, indicating limited year-over-year acceleration in revenue, net income, or EPS as measured from FY2025 10-K data, which constrains the overall composite score.
- The theme sub-score of 0.0/20 reflects zero identifiable macro theme exposures in the model's framework, meaning Abbott does not benefit from scoring uplift tied to secular growth narratives such as AI in healthcare or emerging market expansion.
- The momentum sub-score of 9.8/20 suggests only moderate sequential improvement in quarterly revenue, earnings, and margins, indicating Abbott is not currently experiencing an accelerating fundamental inflection that would elevate the research view.
What Could Change the Picture
Bullish Triggers
- Evidence in a subsequent 10-K filing of accelerating revenue and EPS growth — particularly from FreeStyle Libre or cardiovascular device segments — would likely lift the growth sub-score from 6.0 and push the composite score meaningfully higher.
- Identification of macro theme exposures in future filings, such as quantifiable alignment with aging population healthcare demand or medical AI integration, would raise the theme sub-score above 0.0 and broaden the overall research case.
Bearish Triggers
- A deterioration in the financial health sub-score driven by increased leverage, weakened interest coverage, or a significant reduction in free cash flow as reported in future EDGAR filings would undermine the primary pillar supporting Abbott's current score.
- Any reduction in dividend per share or FCF payout coverage declining below sustainable thresholds in a future 10-K would directly weaken the dividend sub-score of 13.8 and erode Abbott's primary goal profile fit.
Red Flags
- The growth sub-score of 6.0/20 is notably low relative to the sector expectation for a medical device company, raising a question about whether revenue and earnings expansion can sustain the dividend growth trajectory over subsequent filing periods.
Risk Profile
Low RiskAbbott's Low risk rating reflects its combination of a strong financial health sub-score (18.0/20), solid profitability (14.4/20), and consistent dividend coverage as evidenced in its FY2025 EDGAR filing — characteristics associated with financial resilience and predictable cash generation rather than speculative earnings volatility. For a diversified medical device and diagnostics company with established product lines, these balance sheet and cash flow attributes support a lower fundamental risk profile relative to earlier-stage healthcare peers.
Key Catalysts to Watch
The key factor to monitor for Abbott is whether its medical device segments — particularly continuous glucose monitoring and cardiovascular devices — can generate measurable acceleration in revenue and earnings growth in future filings to address the weak growth sub-score. Additionally, any EDGAR-documented expansion into macro-theme-aligned segments would be a notable catalyst for a higher composite model score.
This report is for educational and research purposes only. It does not constitute financial, investment, legal, or tax advice — always conduct your own due diligence before making investment decisions.